Located in Parkville, Melbourne – the epicentre of Australian medical research and innovation, we are a venture-discovery company led by an outstanding team of experts.
We manage a portfolio of investee early-stage biopharmaceutical companies developing platform technologies and delivering first in class/best in class small molecule drugs for indications including oncology and chronic inflammatory diseases. We’re able to accelerate development by sourcing and providing access to capital, expertise and R&D capacity.
SYNthesis med chem CRO was acquired by Viva Biotech (Shanghai) Ltd. for USD 80 Million in 2020.
SYNthesis Research has completed three license deals with major Pharma partners since 2016 through its diverse investments in risk-managed drug discovery & development.